Brian Armstrong

And it starts to, it originally ingested all of the existing literature.

Now it's been ingesting the wet lab data that's been coming out of New Limit, which we have the largest data set out there by far.

And so it recommends the next set of experiments that we run in our wet lab.

We do these pooled screens and see if,

phenotypically, we can make cells look younger.

Then we take the best hits out of that in the funnel and we put them through functional assays, which are a little slower and more expensive, to see if they actually act younger.

For instance, we might take a reprogrammed liver cell and see if it can process caffeine and acetaminophen and alcohol or whatever, kind of like a young liver cell.

And then the best functional assay candidates we then are starting to run through are

non-human primate and human trials.

So yeah, the process has gone faster than I would have expected.

I thought this was going to be like a five or 10 year kind of basic research endeavor, but we've actually been able to demonstrate successful reprogramming of human cells now in our first drug candidates going into the clinic next year, hopefully followed by a bunch more.

I have to go look at his data on that.

I actually, I haven't looked at the exact year that it would be projected to happen.

I'm just been, again, trying to solve more mundane problems.

Like how do we hire, how do we hire the next, you know, bioinformaticist or whatever.

But yeah, I hope he's right.

I mean, he has been right on so many things.

It wouldn't surprise me if he's right again.

Actually, I like your theory.

I like your theory on that, Alex.